Skip to content

Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction

Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07181356
Acronym
L-RICP-AMI
Enrollment
2146
Registered
2025-09-18
Start date
2025-01-01
Completion date
2028-12-01
Last updated
2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Brief summary

At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.

Detailed description

A total of 2146 patients with AMI are expected included as the research objects and randomly divided into experimental group and control group with 1073 cases in each group. After admission, Patients in the experimental group received everyday RIPC of upper limbs to the end of follow-up.The control group is a blank control and undergoes conventional medical procedures. Routine blood indexes, ultrasound, electrocardiogram, were detected On the day of admission. 12 months post- discharge, the incidence of MACCE(include Cardiovascular death, non-fatal acute myocardial infarction, stent thrombosis, revascularization, stroke, admission due to heart failure and the above composite events were independent components) and Poce(All deaths, all strokes, all myocardial infarction, or all revascularization events)will recorded by telephone follow-up.

Interventions

OTHERRIPerC

Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles

OTHERRIPC

Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles

Sponsors

Henan Institute of Cardiovascular Epidemiology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients diagnosed with acute myocardial infarction on admission were immediately assigned to the experimental group and control group

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the Global Unified Definition of Fourth Myocardial Infarction

Exclusion criteria

* The patients could not tolerate RIPC or RIPerC * Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases * The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively * severe liver dysfunction (bilirubin \> 20 mmol / L, prothrombin time \> 2.0 ratio) * Severe renal insufficiency (GFR \< 30 ml / min / 1.73 m2); * patients taking nicorandil and other drugs affecting microcirculation * pregnant

Design outcomes

Primary

MeasureTime frameDescription
Rate of MACCEs12 months after dischargeMACCE(include Cardiovascular death, non-fatal acute myocardial infarction, revascularization, stroke, admission due to heart failure )

Secondary

MeasureTime frameDescription
Rate of non-fatal acute myocardial infarction events12 months after dischargeRate of non-fatal acute myocardial infarction events
Rate of revascularization events12 months after dischargeRate of revascularization events
Rate of Cardiovascular death events12 months after dischargeRate of Cardiovascular death events
Rate of admission due to heart failure events12 months after dischargeRate of admission due to heart failure events
Rate of all all-cause death events12 months after dischargeRate of all all-cause death events
Rate of stroke events12 months after dischargeRate of stroke events

Countries

China

Contacts

Primary ContactMuwei LI
lmw0207@163.com13838083966
Backup ContactGUO QUAN
xinyiguoquan@163.com15670510031

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026